FDA Approves Journey Medical’s Emrosi (Minocycline Hydrochloride Extended Release Capsules) for Treating Rosacea
The U.S. Food and Drug Administration (FDA) has approved Minocycline Hydrochloride Extended Release Capsules, 40 mg (Emrosi, Journey Medical Corporation), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. “The approval of low-dose minocycline offers rosacea sufferers another highly effective option for the oral treatment of rosacea, expanding the […]